Drugs / DGPR1008
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07101354 | Jun → Jul 2024 | prostate cancer | Haitao Niu, MD | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07415135 | Mar → Jun 2026 overdue | prostate cancer | Zhu Yinjie | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07387510 | Feb → Jul 2026 overdue | — | Haitao Niu, MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07024030 | Oct → Dec 2024 | — | Haitao Niu, MD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DGPR1008 | “DGPR1008 (0.04 mg/kg according to each subject's body weight) was given as a single slow infusion 12 hours (±4 hours) preoperatively, after which radical prostatectomy was performed.” NCT07387510 ↗3“PSMA-targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Prostate Cancer” NCT07024030 ↗ |
| Modality | Diagnostic / imaging agent | “Fluorescent Contrast Agent” NCT07024030 ↗ |
| Route | Intravenous | “Intravenous administration will be conducted 24 hours before surgery.” NCT07024030 ↗ |